Filing Flows › Inhibrx Biosciences (INBX) › Q4 2024
Inhibrx Biosciences (INBX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 17, 2025
Inhibrx Biosciences (INBX) reported revenue of $100K for the fourth quarter 2024 (Q4 2024), -94% from a year earlier.
Inhibrx Biosciences, Q4 2024: revenue $100K (-94% year over year), net loss $47.9M, operating cash flow −$43.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $100K | — | -94% |
| Operating profit | −$49.9M | — | — |
| Net earnings | −$47.9M | — | — |
| Operating cash flow | −$43.7M | — | — |
What changed
Revenue was $100K in Q4 2024, down 94% year over year.
Operating costs exceeded revenue by $49.9M, an operating margin of -49928.0%. Total costs fell 44% while revenue fell 94%. The fastest-growing cost line was General & admin (+113%). The quarter ended with a net loss of $47.9M.
Operating cash flow was −$43.7M. Non-cash charges added back $689K of depreciation and amortization and $3.0M of share-based compensation. Capital expenditures of $16K exceeded it, leaving free cash flow of −$43.7M.
Questions
What was Inhibrx Biosciences' revenue in the fourth quarter 2024?
Inhibrx Biosciences (INBX) reported revenue of $100K for the fourth quarter 2024 (Q4 2024), -94% from a year earlier.